Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Beyond being the most important natural compound source, actinomycetes are the origin of up to two-thirds of all clinically used antibiotics. Currently, new antimicrobials are urgently needed, as infections caused by antibiotic-resistant pathogens are on the rise. In the identification of new antibiotics, many scientists are currently investigating biosynthetic aspects of antibiotic production in actinomycetes. Since the emergence of next-generation sequencing technologies, the field of antibiotics research has experienced a remarkable revival. These bacteria have the potential to produce more antibiotics than previously thought possible. Some antibiotics are produced in standard media, while others require the presence of a specific signaling molecule in the medium. Others, however, are only produced when the native regulation of the biosynthesis gene cluster is overruled. This book covers topics in the field of antibiotic-producing actinomycetes. The following tops are addressed: - Approaches to access novel antibiotic producers for novel natural compounds - Omics and genome mining approaches for the discovery of novel natural compounds - Analyses and genetic engineering of antibiotic biosynthesis - Regulation of the secondary metabolism in actinomycetes

Research & information: general --- Biology, life sciences --- Streptomyces --- biogeography --- comparative genomics --- diversification --- secondary metabolite biosynthetic gene clusters --- SMGC --- natural products --- streptomyces --- rishirilide --- biosynthesis --- polyketides --- polynucleotide phosphorylase --- ribonuclease --- regulation --- promoter --- RNA decay --- polyadenylation --- (p)ppGpp --- antibiotic --- antibiotics --- geomicrobiology --- Illumina sequencing --- microbiome diversity --- Actinobacteria --- Cave microbiology --- secondary metabolite --- rare Actinobacteria --- Amycolatopsis --- unculturability --- siderophore --- glycopeptide antibiotics --- dbv cluster --- regulatory genes --- StrR --- LAL --- LuxR solo --- dalbavancin --- A40926 --- Streptomyces lividans --- secretion pathways --- secretory proteins --- signal peptides --- actinomycetes --- teicoplanin --- van resistance genes --- Streptomyces tsukubaensis --- tacrolimus --- FK506 --- omics --- screening --- secondary metabolism --- differentiation --- elicitors --- morphology --- liquid cultures --- metagenomics --- rare actinomycetes --- dereplication --- metabolomics --- genome mining --- secondary metabolites --- novel compounds --- physicochemical screening --- physical and chemical properties --- structural diversity --- biological activity --- Actinoallomurus --- antibiotics polyethers --- lysolipin --- minimal PKS II --- cyclases --- benz[a]naphthacene quinone --- tridecaketide --- aromatic polyketide --- pentacyclic angular polyphenol --- extended polyketide chain --- actinobacteria --- β-lactamase --- resistance --- β-lactamase inhibitor --- polyketide synthases --- acyltransferases --- engineering --- new bioactive compounds --- symbiosis --- drug discovery --- chemical ecology --- culture-based approaches --- strain --- specialized metabolites --- biosynthetic gene cluster --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Beyond being the most important natural compound source, actinomycetes are the origin of up to two-thirds of all clinically used antibiotics. Currently, new antimicrobials are urgently needed, as infections caused by antibiotic-resistant pathogens are on the rise. In the identification of new antibiotics, many scientists are currently investigating biosynthetic aspects of antibiotic production in actinomycetes. Since the emergence of next-generation sequencing technologies, the field of antibiotics research has experienced a remarkable revival. These bacteria have the potential to produce more antibiotics than previously thought possible. Some antibiotics are produced in standard media, while others require the presence of a specific signaling molecule in the medium. Others, however, are only produced when the native regulation of the biosynthesis gene cluster is overruled. This book covers topics in the field of antibiotic-producing actinomycetes. The following tops are addressed: - Approaches to access novel antibiotic producers for novel natural compounds - Omics and genome mining approaches for the discovery of novel natural compounds - Analyses and genetic engineering of antibiotic biosynthesis - Regulation of the secondary metabolism in actinomycetes

Research & information: general --- Biology, life sciences --- Streptomyces --- biogeography --- comparative genomics --- diversification --- secondary metabolite biosynthetic gene clusters --- SMGC --- natural products --- streptomyces --- rishirilide --- biosynthesis --- polyketides --- polynucleotide phosphorylase --- ribonuclease --- regulation --- promoter --- RNA decay --- polyadenylation --- (p)ppGpp --- antibiotic --- antibiotics --- geomicrobiology --- Illumina sequencing --- microbiome diversity --- Actinobacteria --- Cave microbiology --- secondary metabolite --- rare Actinobacteria --- Amycolatopsis --- unculturability --- siderophore --- glycopeptide antibiotics --- dbv cluster --- regulatory genes --- StrR --- LAL --- LuxR solo --- dalbavancin --- A40926 --- Streptomyces lividans --- secretion pathways --- secretory proteins --- signal peptides --- actinomycetes --- teicoplanin --- van resistance genes --- Streptomyces tsukubaensis --- tacrolimus --- FK506 --- omics --- screening --- secondary metabolism --- differentiation --- elicitors --- morphology --- liquid cultures --- metagenomics --- rare actinomycetes --- dereplication --- metabolomics --- genome mining --- secondary metabolites --- novel compounds --- physicochemical screening --- physical and chemical properties --- structural diversity --- biological activity --- Actinoallomurus --- antibiotics polyethers --- lysolipin --- minimal PKS II --- cyclases --- benz[a]naphthacene quinone --- tridecaketide --- aromatic polyketide --- pentacyclic angular polyphenol --- extended polyketide chain --- actinobacteria --- β-lactamase --- resistance --- β-lactamase inhibitor --- polyketide synthases --- acyltransferases --- engineering --- new bioactive compounds --- symbiosis --- drug discovery --- chemical ecology --- culture-based approaches --- strain --- specialized metabolites --- biosynthetic gene cluster --- Streptomyces --- biogeography --- comparative genomics --- diversification --- secondary metabolite biosynthetic gene clusters --- SMGC --- natural products --- streptomyces --- rishirilide --- biosynthesis --- polyketides --- polynucleotide phosphorylase --- ribonuclease --- regulation --- promoter --- RNA decay --- polyadenylation --- (p)ppGpp --- antibiotic --- antibiotics --- geomicrobiology --- Illumina sequencing --- microbiome diversity --- Actinobacteria --- Cave microbiology --- secondary metabolite --- rare Actinobacteria --- Amycolatopsis --- unculturability --- siderophore --- glycopeptide antibiotics --- dbv cluster --- regulatory genes --- StrR --- LAL --- LuxR solo --- dalbavancin --- A40926 --- Streptomyces lividans --- secretion pathways --- secretory proteins --- signal peptides --- actinomycetes --- teicoplanin --- van resistance genes --- Streptomyces tsukubaensis --- tacrolimus --- FK506 --- omics --- screening --- secondary metabolism --- differentiation --- elicitors --- morphology --- liquid cultures --- metagenomics --- rare actinomycetes --- dereplication --- metabolomics --- genome mining --- secondary metabolites --- novel compounds --- physicochemical screening --- physical and chemical properties --- structural diversity --- biological activity --- Actinoallomurus --- antibiotics polyethers --- lysolipin --- minimal PKS II --- cyclases --- benz[a]naphthacene quinone --- tridecaketide --- aromatic polyketide --- pentacyclic angular polyphenol --- extended polyketide chain --- actinobacteria --- β-lactamase --- resistance --- β-lactamase inhibitor --- polyketide synthases --- acyltransferases --- engineering --- new bioactive compounds --- symbiosis --- drug discovery --- chemical ecology --- culture-based approaches --- strain --- specialized metabolites --- biosynthetic gene cluster

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Biomarkers are measures of a biological state. The treatment of individual patients based on particular factors, such as biomarkers, distinguishes standard, generalized treatment plans from personalized medicine. Even though personalized medicine is applicable to most branches of medicine, the field of oncology is perhaps where it is most easily employed. Cancer is a heterogeneous disease; although patients may be diagnosed histologically with the same cancer type, their tumors can comprise varying tumor microenvironments and molecular characteristics that can impact treatment response and prognosis. There has been a major drive over the past decade to try and realize personalized cancer medicine through the discovery and use of disease-specific biomarkers. This book, entitled “Cancer Biomarker Research and Personalized Medicine”, encompasses 22 publications from colleagues working on a diverse range of cancers, including prostate, breast, ovarian, head and neck, liver, gastric, bladder, colorectal, and kidney. The biomarkers assessed in these studies include genes, intracellular or secreted proteins, exosomes, DNA, RNA, miRNA, circulating tumor cells, circulating immune cells, in addition to radiomic features.

Medicine --- Oncology --- clear cell renal cell carcinoma --- radiomics --- WHO/ISUP nuclear grade --- multiphasic multidetector computed tomography --- triple-negative breast cancer --- taxane --- chemotherapy --- GBP5 --- Akt/mTOR --- autophagy --- IL13Rα2 --- renal cell carcinoma --- JAK2 --- FOXO3 --- telmisartan --- ovarian cancer --- bioinformatics --- CREB1 --- drug perturbation --- lincRNA-p21 --- rectal cancer --- chemoradiotherapy --- colorectal cancer --- long non-coding RNA --- p53 --- predictive biomarker --- intestinal anastomosis --- anastomotic leak --- biomarkers --- precision medicine --- personalized medicine --- biomarker --- AmpliSeq --- DNA methylation --- epigenetics --- head and neck cancer --- saliva --- liquid biopsy --- meta-analysis --- gastric cancer --- middle-up-down --- haptoglobin --- glycopeptide --- mass spectrometry --- circulating tumor cells --- prostate cancer --- cancer vaccine --- immune response --- breast cancer --- predictive tools --- prognostic tools --- translational research --- IL6ST --- gp130 --- cytokine signalling --- tissue-based biomarkers --- liquid-based biomarkers --- radiotherapy --- radiosensitivity biomarkers --- secretome --- radioresistance --- bladder tumor --- lymphocyte-to-monocyte ratio --- peripheral blood parameters --- tumor recurrence --- transurethral resection --- lipidomics --- 1H-NMR --- LC-MS/MS --- lipoprotein subfractions --- lipoprotein lipase --- cancer biomarkers --- hepatocellular carcinoma --- p16 expression --- head and neck squamous cell carcinoma --- HPV genotyping --- exosomes --- chemoresistance --- comparative oncology --- One Health --- microRNA --- lymph node metastasis --- hormone-dependent carcinogenesis --- localized prostate cancer --- prognostic factors --- HNSCC --- clear cell renal cell carcinoma --- radiomics --- WHO/ISUP nuclear grade --- multiphasic multidetector computed tomography --- triple-negative breast cancer --- taxane --- chemotherapy --- GBP5 --- Akt/mTOR --- autophagy --- IL13Rα2 --- renal cell carcinoma --- JAK2 --- FOXO3 --- telmisartan --- ovarian cancer --- bioinformatics --- CREB1 --- drug perturbation --- lincRNA-p21 --- rectal cancer --- chemoradiotherapy --- colorectal cancer --- long non-coding RNA --- p53 --- predictive biomarker --- intestinal anastomosis --- anastomotic leak --- biomarkers --- precision medicine --- personalized medicine --- biomarker --- AmpliSeq --- DNA methylation --- epigenetics --- head and neck cancer --- saliva --- liquid biopsy --- meta-analysis --- gastric cancer --- middle-up-down --- haptoglobin --- glycopeptide --- mass spectrometry --- circulating tumor cells --- prostate cancer --- cancer vaccine --- immune response --- breast cancer --- predictive tools --- prognostic tools --- translational research --- IL6ST --- gp130 --- cytokine signalling --- tissue-based biomarkers --- liquid-based biomarkers --- radiotherapy --- radiosensitivity biomarkers --- secretome --- radioresistance --- bladder tumor --- lymphocyte-to-monocyte ratio --- peripheral blood parameters --- tumor recurrence --- transurethral resection --- lipidomics --- 1H-NMR --- LC-MS/MS --- lipoprotein subfractions --- lipoprotein lipase --- cancer biomarkers --- hepatocellular carcinoma --- p16 expression --- head and neck squamous cell carcinoma --- HPV genotyping --- exosomes --- chemoresistance --- comparative oncology --- One Health --- microRNA --- lymph node metastasis --- hormone-dependent carcinogenesis --- localized prostate cancer --- prognostic factors --- HNSCC

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Biomarkers are measures of a biological state. The treatment of individual patients based on particular factors, such as biomarkers, distinguishes standard, generalized treatment plans from personalized medicine. Even though personalized medicine is applicable to most branches of medicine, the field of oncology is perhaps where it is most easily employed. Cancer is a heterogeneous disease; although patients may be diagnosed histologically with the same cancer type, their tumors can comprise varying tumor microenvironments and molecular characteristics that can impact treatment response and prognosis. There has been a major drive over the past decade to try and realize personalized cancer medicine through the discovery and use of disease-specific biomarkers. This book, entitled “Cancer Biomarker Research and Personalized Medicine”, encompasses 22 publications from colleagues working on a diverse range of cancers, including prostate, breast, ovarian, head and neck, liver, gastric, bladder, colorectal, and kidney. The biomarkers assessed in these studies include genes, intracellular or secreted proteins, exosomes, DNA, RNA, miRNA, circulating tumor cells, circulating immune cells, in addition to radiomic features.

Medicine --- Oncology --- clear cell renal cell carcinoma --- radiomics --- WHO/ISUP nuclear grade --- multiphasic multidetector computed tomography --- triple-negative breast cancer --- taxane --- chemotherapy --- GBP5 --- Akt/mTOR --- autophagy --- IL13Rα2 --- renal cell carcinoma --- JAK2 --- FOXO3 --- telmisartan --- ovarian cancer --- bioinformatics --- CREB1 --- drug perturbation --- lincRNA-p21 --- rectal cancer --- chemoradiotherapy --- colorectal cancer --- long non-coding RNA --- p53 --- predictive biomarker --- intestinal anastomosis --- anastomotic leak --- biomarkers --- precision medicine --- personalized medicine --- biomarker --- AmpliSeq --- DNA methylation --- epigenetics --- head and neck cancer --- saliva --- liquid biopsy --- meta-analysis --- gastric cancer --- middle-up-down --- haptoglobin --- glycopeptide --- mass spectrometry --- circulating tumor cells --- prostate cancer --- cancer vaccine --- immune response --- breast cancer --- predictive tools --- prognostic tools --- translational research --- IL6ST --- gp130 --- cytokine signalling --- tissue-based biomarkers --- liquid-based biomarkers --- radiotherapy --- radiosensitivity biomarkers --- secretome --- radioresistance --- bladder tumor --- lymphocyte-to-monocyte ratio --- peripheral blood parameters --- tumor recurrence --- transurethral resection --- lipidomics --- 1H-NMR --- LC-MS/MS --- lipoprotein subfractions --- lipoprotein lipase --- cancer biomarkers --- hepatocellular carcinoma --- p16 expression --- head and neck squamous cell carcinoma --- HPV genotyping --- exosomes --- chemoresistance --- comparative oncology --- One Health --- microRNA --- lymph node metastasis --- hormone-dependent carcinogenesis --- localized prostate cancer --- prognostic factors --- HNSCC --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Biomarkers are measures of a biological state. The treatment of individual patients based on particular factors, such as biomarkers, distinguishes standard, generalized treatment plans from personalized medicine. Even though personalized medicine is applicable to most branches of medicine, the field of oncology is perhaps where it is most easily employed. Cancer is a heterogeneous disease; although patients may be diagnosed histologically with the same cancer type, their tumors can comprise varying tumor microenvironments and molecular characteristics that can impact treatment response and prognosis. There has been a major drive over the past decade to try and realize personalized cancer medicine through the discovery and use of disease-specific biomarkers. This book, entitled “Cancer Biomarker Research and Personalized Medicine”, encompasses 22 publications from colleagues working on a diverse range of cancers, including prostate, breast, ovarian, head and neck, liver, gastric, bladder, colorectal, and kidney. The biomarkers assessed in these studies include genes, intracellular or secreted proteins, exosomes, DNA, RNA, miRNA, circulating tumor cells, circulating immune cells, in addition to radiomic features.

clear cell renal cell carcinoma --- radiomics --- WHO/ISUP nuclear grade --- multiphasic multidetector computed tomography --- triple-negative breast cancer --- taxane --- chemotherapy --- GBP5 --- Akt/mTOR --- autophagy --- IL13Rα2 --- renal cell carcinoma --- JAK2 --- FOXO3 --- telmisartan --- ovarian cancer --- bioinformatics --- CREB1 --- drug perturbation --- lincRNA-p21 --- rectal cancer --- chemoradiotherapy --- colorectal cancer --- long non-coding RNA --- p53 --- predictive biomarker --- intestinal anastomosis --- anastomotic leak --- biomarkers --- precision medicine --- personalized medicine --- biomarker --- AmpliSeq --- DNA methylation --- epigenetics --- head and neck cancer --- saliva --- liquid biopsy --- meta-analysis --- gastric cancer --- middle-up-down --- haptoglobin --- glycopeptide --- mass spectrometry --- circulating tumor cells --- prostate cancer --- cancer vaccine --- immune response --- breast cancer --- predictive tools --- prognostic tools --- translational research --- IL6ST --- gp130 --- cytokine signalling --- tissue-based biomarkers --- liquid-based biomarkers --- radiotherapy --- radiosensitivity biomarkers --- secretome --- radioresistance --- bladder tumor --- lymphocyte-to-monocyte ratio --- peripheral blood parameters --- tumor recurrence --- transurethral resection --- lipidomics --- 1H-NMR --- LC-MS/MS --- lipoprotein subfractions --- lipoprotein lipase --- cancer biomarkers --- hepatocellular carcinoma --- p16 expression --- head and neck squamous cell carcinoma --- HPV genotyping --- exosomes --- chemoresistance --- comparative oncology --- One Health --- microRNA --- lymph node metastasis --- hormone-dependent carcinogenesis --- localized prostate cancer --- prognostic factors --- HNSCC --- n/a